Evidence-based screening, early diagnosis and treatment strategy of cervical cancer for national policy in lowresource countries: Example of India

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1699-1703

  Saxena, Upma ^a   Sauvaget, Catherine ^b   Sankaranarayanan, Rengaswamy ^b  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical neoplasm; Early detection; Low income countries; Screen and treat approach; Screening methods

Indexed keywords

DEVELOPING COUNTRY; EARLY DIAGNOSIS; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE POLICY; HUMAN; INDIA; METHODOLOGY; REVIEW; UTERINE CERVIX TUMOR;

DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH POLICY; HUMANS; INDIA; UTERINE CERVICAL NEOPLASMS;

EID: 84873037027     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1699     Document Type: Article

References (41)

1. Almonte M, Ferreccio C, Winkler JL, et al (2007). Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer, 121, 796-802.
2. Basu P, Roychowdhury S, Bafna UD, et al (2009). Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev, 10, 27-34.
3. Belinson J, Qiao Y, Pretorius R, et al (1999). Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer, 9, 411-7.
4. Belinson SE, Belinson JL (2010). Human papillomavirus DNA testing for cervical cancer screening: practical aspects in developing countries. Mol Diagn Ther, 14, 215-22.
5. Bhatla N, Dar L, Patro AR, et al (2006). Human papillomavirus type distribution in cervical cancer in Delhi, India. Int J Gynecol Pathol, 25, 398-402.
6. Castro W, Gage J, Gaffikin L, et al (2003) 'Effectiveness, safety, and acceptability of cryotherapy: a systematic literature review: Cervical Cancer Prevention Issues in Depth # 1.' Alliance for Cervical Cancer Prevention (ACCP): Seattle
7. Cole P, Morrison AS (1980). Basic issues in population screening for cancer. J Natl Cancer Inst, 64, 1263-72.
8. Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101.
9. Denny L, Kuhn L, De SM, et al (2005). Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA, 294, 2173-2181.
10. Denny L, Kuhn L, Hu CC, et al (2010). Human papillomavirusbased cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst, 102, 1557-67.
11. Dzuba IG, Calderon R, Bliesner S, et al (2005). A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. Rev Panam Salud Publica, 18, 53-63.
12. Ferlay J, Shin HR, Bray F, et al(2010) 'GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].' International Agency for Research on Cancer: Lyon.
13. Franceschi S, Denny L, Irwin KL, et al (2011). Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer, 128, 2765-2774.
14. Franco EL (2010). Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough? J Natl Cancer Inst, 102, 1451-3.
15. Gaffikin L, Blumenthal PD, Emerson M, et al (2003). Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet, 361, 814-20.
16. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al (2005). Costeffectiveness of cervical-cancer screening in five developing countries. N Engl J Med, 353, 2158-68.
17. Gravitt PE, Coutlee F, Iftner T, et al (2008). New technologies in cervical cancer screening. Vaccine, 26 Suppl 10, K42-K52.
18. International Agency for Research on Cancer (2005) 'IARC Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening.' IARCPress: Lyon.
19. Megevand E, Denny L, Dehaeck K, et al (1996). Acetic acid visualization of the cervix: an alternative to cytologic screening. Obstet Gynecol, 88, 383-6.
20. Moodley J, Kawonga M, Bradley J, et al (2006). Challenges in implementing a cervical screening program in South Africa. Cancer Detect Prev, 30, 361-8.
21. Muwonge R, Manuel MG, Filipe AP, et al (2010). Visual screening for early detection of cervical neoplasia in Angola. Int J Gynaecol Obstet, 111, 68-72.
22. National Cancer Registry Programme (2007) 'Consolidated report of hospital based cancer registries 2001-2003.' NCPR, ICMR: Bangalore.
23. National Cancer Registry Programme (2009) 'Time trends in cancer incidence rates: 1982-2005.' NCRP, ICMR: Bangalore.
24. Ngoma T, Muwonge R, Mwaiselage J, et al (2010). Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania. Int J Gynaecol Obstet, 109, 100-4.
25. Qiao YL, Sellors JW, Eder PS, et al (2008). A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 9, 929-36.
26. Sankaranarayanan R, Basu P, Wesley RS, et al (2004a). Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer, 110, 907-13.
27. Sankaranarayanan R, Budukh AM, Rajkumar R (2001). Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull WHO, 79, 954-62.
28. Sankaranarayanan R, Esmy PO, Rajkumar R, et al (2007a). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet, 370, 398-406.
29. Sankaranarayanan R, Gaffikin L, Jacob M, et al (2005a). A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet, 89 Suppl 2, S4-S12.
30. Sankaranarayanan R, Nene BM, Dinshaw KA, et al (2005b). A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer, 116, 617-623.
31. Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural India. N Engl J Med, 360, 1385-94.
32. Sankaranarayanan R, Rajkumar R, Esmy PO, et al (2007b). Effectiveness, safety and acceptability of 'see and treat' with cryotherapy by nurses in a cervical screening study in India. Br J Cancer, 96, 738-43.
33. Sankaranarayanan R, Thara S, Sharma A, et al (2004b). Accuracy of conventional cytology: results from a multicentre screening study in India. J Med Screen, 11, 77-84.
34. Sarian LO, Derchain SF, Naud P, et al (2005). Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen, 12, 142-9.
35. Sauvaget C, Fayette JM, Muwonge R, et al (2011). Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet, 113, 14-24.
36. Schiffman M, Wentzensen N (2010). From human papillomavirus to cervical cancer. Obstet Gynecol, 116, 177-85.
37. Sherris J, Wittet S, Kleine A, et al (2009). Evidence-based, alternative cervical cancer screening approaches in lowresource settings. Int Perspect Sex Reprod Health, 35, 147-54.
38. University of Zimbabwe/JHPIEGO Cervical Cancer Project (1999). Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. Lancet, 353, 869-73.
39. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-19.
40. World Health Organization (2001) 'Macroeconomics and health: investing in health for economic development. Report of the commission on Macroeconomics and health.' WHO: Geneva.
41. World Health Organization (2009) 'The global burden of disease: Death and DALY estimates for 2004 by cause for WHO member States, 2004 Update.' WHO: Geneva.